Veracyte
Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in improving patient care through advanced genomic testing. The company offers a range of diagnostic products, including the Afirma Genomic Sequencing Classifier for thyroid cancer, the Percepta Genomic Sequencing Classifier for lung cancer, the Envisia Genomic Classifier for idiopathic pulmonary fibrosis, and the Prosigna Breast Cancer Prognostic Gene Signature Assay. These tests help identify benign conditions, differentiate diseases, and assess cancer recurrence risk, thereby reducing the need for invasive procedures and expediting treatment decisions. Veracyte collaborates with various organizations, including Johnson & Johnson, to enhance the development and commercialization of innovative diagnostic tests. With a commitment to leveraging genomic science and technology, Veracyte aims to deliver effective solutions for patients and healthcare providers globally.
C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers liquid biopsy services that analyze subtle changes in tumor DNA to provide insights into cancer progression and recurrence. This technology enables the development of a bio-platform approach applicable across various cancer types, facilitating the guidance of diverse treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enhancing the ability of healthcare providers to monitor treatment responses and detect recurrences or failures earlier than traditional methods allow. Founded in 2019 and headquartered in New York, with a research and development center in Haifa, Israel, C2i Genomics aims to improve the lives and outcomes of cancer patients through innovative diagnostic solutions.
HalioDx is a company focused on designing and developing diagnostic tests in oncology that assess the immune contexture of cancers. It offers a range of immunologic scoring tests that investigate the immune response within the tumor environment. Utilizing a proprietary set of immune biomarkers and advanced image analysis technologies, HalioDx's tests accurately measure the immune reaction in and around tumors. This information helps clinicians evaluate the severity of a patient's disease and predict their response to treatment, ultimately aiding in personalized patient care.
Decipher Biosciences offers a portfolio of genomic tests, continues to build the GRID database of over 70,000 whole transcriptome profiles, and is partnering with pharmaceutical companies to identify biomarkers of response to novel therapeutics.
Allegro Diagnostics, founded in 2006 by Dr. Jerome Brody and Dr. Avrum Spira, is a molecular diagnostics company based in Maynard, Massachusetts. The company specializes in the development and commercialization of genomic tests aimed at diagnosing, staging, and guiding the treatment of lung cancer and other lung diseases. Allegro's molecular testing platform employs a genomic biomarker to assess changes in gene expression in the airway's epithelial cells, allowing for the early detection of lung cancer, particularly in current and former smokers. This innovative approach provides healthcare providers with essential diagnostic information, facilitating quicker diagnosis and treatment decisions for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.